Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion
Abstract The effect of IV physostigmine administration on the cerebrospinal fluid (CSF) levels of homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC) in normal subjects was determined. After an adjustment for differing CSF concentrations of probenecid, physostigmine was found to elevate C...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1981 |
|---|
| Umfang: |
6 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: Psychopharmacology - 1959, 72(1981) vom: Feb., Seite 155-160 |
| Übergeordnetes Werk: |
volume:72 ; year:1981 ; month:02 ; pages:155-160 ; extent:6 |
| Links: |
|---|
| Katalog-ID: |
NLEJ200777718 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ200777718 | ||
| 003 | DE-627 | ||
| 005 | 20210706060807.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070527s1981 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ200777718 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion |
| 264 | 1 | |c 1981 | |
| 300 | |a 6 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Abstract The effect of IV physostigmine administration on the cerebrospinal fluid (CSF) levels of homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC) in normal subjects was determined. After an adjustment for differing CSF concentrations of probenecid, physostigmine was found to elevate CSF HVA and DOPAC concentrations. The authors discuss these changes in CSF HVA and DOPAC and their possible relationship to the ability of physostigmine to decrease the symptoms of some patients with tardive dyskinesia. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Davis, Kenneth L. |4 oth | |
| 700 | 1 | |a Faull, Kym F. |4 oth | |
| 700 | 1 | |a Hollister, Leo E. |4 oth | |
| 700 | 1 | |a Barchas, Jack D. |4 oth | |
| 700 | 1 | |a Berger, Philip A. |4 oth | |
| 773 | 0 | 8 | |i in |t Psychopharmacology |d 1959 |g 72(1981) vom: Feb., Seite 155-160 |w (DE-627)NLEJ188990615 |w (DE-600)2066933-1 |x 1432-2072 |7 nnns |
| 773 | 1 | 8 | |g volume:72 |g year:1981 |g month:02 |g pages:155-160 |g extent:6 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/BF00431649 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 72 |j 1981 |c 2 |h 155-160 |g 6 | ||
| matchkey_str |
article:14322072:1981----::leainicrbopnllidpmnmtbltsolwnp |
|---|---|
| hierarchy_sort_str |
1981 |
| publishDate |
1981 |
| allfields |
(DE-627)NLEJ200777718 DE-627 ger DE-627 rakwb eng Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion 1981 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract The effect of IV physostigmine administration on the cerebrospinal fluid (CSF) levels of homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC) in normal subjects was determined. After an adjustment for differing CSF concentrations of probenecid, physostigmine was found to elevate CSF HVA and DOPAC concentrations. The authors discuss these changes in CSF HVA and DOPAC and their possible relationship to the ability of physostigmine to decrease the symptoms of some patients with tardive dyskinesia. Springer Online Journal Archives 1860-2002 Davis, Kenneth L. oth Faull, Kym F. oth Hollister, Leo E. oth Barchas, Jack D. oth Berger, Philip A. oth in Psychopharmacology 1959 72(1981) vom: Feb., Seite 155-160 (DE-627)NLEJ188990615 (DE-600)2066933-1 1432-2072 nnns volume:72 year:1981 month:02 pages:155-160 extent:6 http://dx.doi.org/10.1007/BF00431649 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 72 1981 2 155-160 6 |
| spelling |
(DE-627)NLEJ200777718 DE-627 ger DE-627 rakwb eng Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion 1981 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract The effect of IV physostigmine administration on the cerebrospinal fluid (CSF) levels of homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC) in normal subjects was determined. After an adjustment for differing CSF concentrations of probenecid, physostigmine was found to elevate CSF HVA and DOPAC concentrations. The authors discuss these changes in CSF HVA and DOPAC and their possible relationship to the ability of physostigmine to decrease the symptoms of some patients with tardive dyskinesia. Springer Online Journal Archives 1860-2002 Davis, Kenneth L. oth Faull, Kym F. oth Hollister, Leo E. oth Barchas, Jack D. oth Berger, Philip A. oth in Psychopharmacology 1959 72(1981) vom: Feb., Seite 155-160 (DE-627)NLEJ188990615 (DE-600)2066933-1 1432-2072 nnns volume:72 year:1981 month:02 pages:155-160 extent:6 http://dx.doi.org/10.1007/BF00431649 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 72 1981 2 155-160 6 |
| allfields_unstemmed |
(DE-627)NLEJ200777718 DE-627 ger DE-627 rakwb eng Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion 1981 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract The effect of IV physostigmine administration on the cerebrospinal fluid (CSF) levels of homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC) in normal subjects was determined. After an adjustment for differing CSF concentrations of probenecid, physostigmine was found to elevate CSF HVA and DOPAC concentrations. The authors discuss these changes in CSF HVA and DOPAC and their possible relationship to the ability of physostigmine to decrease the symptoms of some patients with tardive dyskinesia. Springer Online Journal Archives 1860-2002 Davis, Kenneth L. oth Faull, Kym F. oth Hollister, Leo E. oth Barchas, Jack D. oth Berger, Philip A. oth in Psychopharmacology 1959 72(1981) vom: Feb., Seite 155-160 (DE-627)NLEJ188990615 (DE-600)2066933-1 1432-2072 nnns volume:72 year:1981 month:02 pages:155-160 extent:6 http://dx.doi.org/10.1007/BF00431649 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 72 1981 2 155-160 6 |
| allfieldsGer |
(DE-627)NLEJ200777718 DE-627 ger DE-627 rakwb eng Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion 1981 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract The effect of IV physostigmine administration on the cerebrospinal fluid (CSF) levels of homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC) in normal subjects was determined. After an adjustment for differing CSF concentrations of probenecid, physostigmine was found to elevate CSF HVA and DOPAC concentrations. The authors discuss these changes in CSF HVA and DOPAC and their possible relationship to the ability of physostigmine to decrease the symptoms of some patients with tardive dyskinesia. Springer Online Journal Archives 1860-2002 Davis, Kenneth L. oth Faull, Kym F. oth Hollister, Leo E. oth Barchas, Jack D. oth Berger, Philip A. oth in Psychopharmacology 1959 72(1981) vom: Feb., Seite 155-160 (DE-627)NLEJ188990615 (DE-600)2066933-1 1432-2072 nnns volume:72 year:1981 month:02 pages:155-160 extent:6 http://dx.doi.org/10.1007/BF00431649 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 72 1981 2 155-160 6 |
| allfieldsSound |
(DE-627)NLEJ200777718 DE-627 ger DE-627 rakwb eng Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion 1981 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract The effect of IV physostigmine administration on the cerebrospinal fluid (CSF) levels of homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC) in normal subjects was determined. After an adjustment for differing CSF concentrations of probenecid, physostigmine was found to elevate CSF HVA and DOPAC concentrations. The authors discuss these changes in CSF HVA and DOPAC and their possible relationship to the ability of physostigmine to decrease the symptoms of some patients with tardive dyskinesia. Springer Online Journal Archives 1860-2002 Davis, Kenneth L. oth Faull, Kym F. oth Hollister, Leo E. oth Barchas, Jack D. oth Berger, Philip A. oth in Psychopharmacology 1959 72(1981) vom: Feb., Seite 155-160 (DE-627)NLEJ188990615 (DE-600)2066933-1 1432-2072 nnns volume:72 year:1981 month:02 pages:155-160 extent:6 http://dx.doi.org/10.1007/BF00431649 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 72 1981 2 155-160 6 |
| language |
English |
| source |
in Psychopharmacology 72(1981) vom: Feb., Seite 155-160 volume:72 year:1981 month:02 pages:155-160 extent:6 |
| sourceStr |
in Psychopharmacology 72(1981) vom: Feb., Seite 155-160 volume:72 year:1981 month:02 pages:155-160 extent:6 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Psychopharmacology |
| authorswithroles_txt_mv |
Davis, Kenneth L. @@oth@@ Faull, Kym F. @@oth@@ Hollister, Leo E. @@oth@@ Barchas, Jack D. @@oth@@ Berger, Philip A. @@oth@@ |
| publishDateDaySort_date |
1981-02-01T00:00:00Z |
| hierarchy_top_id |
NLEJ188990615 |
| id |
NLEJ200777718 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ200777718</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210706060807.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070527s1981 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ200777718</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1981</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract The effect of IV physostigmine administration on the cerebrospinal fluid (CSF) levels of homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC) in normal subjects was determined. After an adjustment for differing CSF concentrations of probenecid, physostigmine was found to elevate CSF HVA and DOPAC concentrations. The authors discuss these changes in CSF HVA and DOPAC and their possible relationship to the ability of physostigmine to decrease the symptoms of some patients with tardive dyskinesia.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Davis, Kenneth L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Faull, Kym F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hollister, Leo E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Barchas, Jack D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berger, Philip A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Psychopharmacology</subfield><subfield code="d">1959</subfield><subfield code="g">72(1981) vom: Feb., Seite 155-160</subfield><subfield code="w">(DE-627)NLEJ188990615</subfield><subfield code="w">(DE-600)2066933-1</subfield><subfield code="x">1432-2072</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:72</subfield><subfield code="g">year:1981</subfield><subfield code="g">month:02</subfield><subfield code="g">pages:155-160</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF00431649</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">72</subfield><subfield code="j">1981</subfield><subfield code="c">2</subfield><subfield code="h">155-160</subfield><subfield code="g">6</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ188990615 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1432-2072 |
| topic_title |
Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
k l d kl kld k f f kf kff l e h le leh j d b jd jdb p a b pa pab |
| hierarchy_parent_title |
Psychopharmacology |
| hierarchy_parent_id |
NLEJ188990615 |
| hierarchy_top_title |
Psychopharmacology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ188990615 (DE-600)2066933-1 |
| title |
Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion |
| spellingShingle |
Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion |
| ctrlnum |
(DE-627)NLEJ200777718 |
| title_full |
Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion |
| journal |
Psychopharmacology |
| journalStr |
Psychopharmacology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1981 |
| contenttype_str_mv |
zzz |
| container_start_page |
155 |
| container_volume |
72 |
| physical |
6 |
| format_se |
Elektronische Aufsätze |
| title_sort |
alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion |
| title_auth |
Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion |
| abstract |
Abstract The effect of IV physostigmine administration on the cerebrospinal fluid (CSF) levels of homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC) in normal subjects was determined. After an adjustment for differing CSF concentrations of probenecid, physostigmine was found to elevate CSF HVA and DOPAC concentrations. The authors discuss these changes in CSF HVA and DOPAC and their possible relationship to the ability of physostigmine to decrease the symptoms of some patients with tardive dyskinesia. |
| abstractGer |
Abstract The effect of IV physostigmine administration on the cerebrospinal fluid (CSF) levels of homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC) in normal subjects was determined. After an adjustment for differing CSF concentrations of probenecid, physostigmine was found to elevate CSF HVA and DOPAC concentrations. The authors discuss these changes in CSF HVA and DOPAC and their possible relationship to the ability of physostigmine to decrease the symptoms of some patients with tardive dyskinesia. |
| abstract_unstemmed |
Abstract The effect of IV physostigmine administration on the cerebrospinal fluid (CSF) levels of homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC) in normal subjects was determined. After an adjustment for differing CSF concentrations of probenecid, physostigmine was found to elevate CSF HVA and DOPAC concentrations. The authors discuss these changes in CSF HVA and DOPAC and their possible relationship to the ability of physostigmine to decrease the symptoms of some patients with tardive dyskinesia. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion |
| url |
http://dx.doi.org/10.1007/BF00431649 |
| remote_bool |
true |
| author2 |
Davis, Kenneth L. Faull, Kym F. Hollister, Leo E. Barchas, Jack D. Berger, Philip A. |
| author2Str |
Davis, Kenneth L. Faull, Kym F. Hollister, Leo E. Barchas, Jack D. Berger, Philip A. |
| ppnlink |
NLEJ188990615 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth |
| up_date |
2024-07-06T03:50:37.499Z |
| _version_ |
1803800110693351424 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ200777718</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210706060807.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070527s1981 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ200777718</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1981</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract The effect of IV physostigmine administration on the cerebrospinal fluid (CSF) levels of homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC) in normal subjects was determined. After an adjustment for differing CSF concentrations of probenecid, physostigmine was found to elevate CSF HVA and DOPAC concentrations. The authors discuss these changes in CSF HVA and DOPAC and their possible relationship to the ability of physostigmine to decrease the symptoms of some patients with tardive dyskinesia.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Davis, Kenneth L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Faull, Kym F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hollister, Leo E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Barchas, Jack D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berger, Philip A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Psychopharmacology</subfield><subfield code="d">1959</subfield><subfield code="g">72(1981) vom: Feb., Seite 155-160</subfield><subfield code="w">(DE-627)NLEJ188990615</subfield><subfield code="w">(DE-600)2066933-1</subfield><subfield code="x">1432-2072</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:72</subfield><subfield code="g">year:1981</subfield><subfield code="g">month:02</subfield><subfield code="g">pages:155-160</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF00431649</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">72</subfield><subfield code="j">1981</subfield><subfield code="c">2</subfield><subfield code="h">155-160</subfield><subfield code="g">6</subfield></datafield></record></collection>
|
| score |
7.3987722 |